International Funding for Malaria Control in Relation to Populations at Risk of Stable Plasmodium falciparum Transmission

Robert W. Snow1,2*, Carlos A. Guerra1,3, Juliette J. Mutheu1, Simon I. Hay1,3
1 Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, Kenyan Medical Research Institute (KEMRI)–University of Oxford–Wellcome Trust Collaborative Programme, Nairobi, Kenya, 2 Centre for Tropical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom, 3 Spatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford, Oxford, United Kingdom

Funding: RWS is a Wellcome Trust Principal Research Fellow (#079080). CAG is supported by a Wellcome Trust Project grant (#076951). SIH is funded by a Senior Research Fellowship from the Wellcome Trust, U.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Academic Editor: Sanjeev Krishna, University of London, United Kingdom

Citation: Snow RW, Guerra CA, Mutheu JJ, Hay SI (2008) International funding for malaria control in relation to populations at risk of stable Plasmodium falciparum transmission. PLoS Med 5(7): e142. doi:10.1371/journal.pmed.0050142

Received: February 4, 2008
Accepted: May 14, 2008
Published: July 22, 2008

Copyright: © 2008 Snow et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: DFID, Department for International Development, UK; GFATM, The Global Fund to fight AIDS, Tuberculosis and Malaria; MDG, Millennium Development Goals; p.a., per annum; PMEC, Plasmodium falciparum malaria endemic country; PPAR, population(s) at risk of P. falciparum malaria; PPARstable, population(s) at stable risk of P. falciparum malaria; PMI, President’s Malaria Initiative; RBM, Roll Back Malaria; USAID, United States Agency for International Development; WMR, World Malaria Report.

* To whom correspondence should be addressed. E-mail: rsnow@nairobi.kemri-wellcome.org

ABSTRACT

Background

The international financing of malaria control has increased significantly in the last ten years in parallel with calls to halve the malaria burden by the year 2015. The allocation of funds to countries should reflect the size of the populations at risk of infection, disease, and death. To examine this relationship, we compare an audit of international commitments with an objective assessment of national need: the population at risk of stable Plasmodium falciparum malaria transmission in 2007.

Methods and Findings

The national distributions of populations at risk of stable P. falciparum transmission were projected to the year 2007 for each of 87 P. falciparum–endemic countries. Systematic online- and literature-based searches were conducted to audit the international funding commitments made for malaria control by major donors between 2002 and 2007. These figures were used to generate annual malaria funding allocation (in US dollars) per capita population at risk of stable P. falciparum in 2007. Almost US$1 billion are distributed each year to the 1.4 billion people exposed to stable P. falciparum malaria risk. This is less than US$1 per person at risk per year. Forty percent of this total comes from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Substantial regional and national variations in disbursements exist. While the distribution of funds is found to be broadly appropriate, specific high population density countries receive disproportionately less support to scale up malaria control. Additionally, an inadequacy of current financial commitments by the international community was found: under-funding could be from 50% to 450%, depending on which global assessment of the cost required to scale up malaria control is adopted.

Conclusions

Without further increases in funding and appropriate targeting of global malaria control investment it is unlikely that international goals to halve disease burdens by 2015 will be achieved. Moreover, the additional financing requirements to move from malaria control to malaria elimination have not yet been considered by the scientific or international community.

The Editors’ Summary of this article follows the references.
Introduction

The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFTAM) [1–3] was established in January 2002 as an independent financing body to attract, manage, and disburse funds to control these three major diseases of poverty. This innovative mechanism for results-based health care financing had by the end of 2007 committed US$10 billion to 136 countries [1,2]. The GFTAM responds to nationally documented demand for antimalarial interventions and commodities. Countries are encouraged to submit proposals every year, which are reviewed independently by a technical review panel before the GFTAM board makes a decision [4,5]. The GFTAM state that their funding priorities are to countries/regions with the highest disease burdens and weakest financial capacity to support disease control [1,6]. By the end of 2006 GFTAM support represented an estimated 64% of all international funding for malaria control worldwide [6,7]. Rather than displace international support for malaria, new funding initiatives have emerged in recent years parallel to the GFTAM, notably the World Bank global strategy and booster program [8] and the US President’s Malaria Initiative (PMI) [9]. Bilateral agencies also continue to expand their support to countries as part of combined efforts to meet the Millennium Development Goals (MDG) [10,11]. As the funding capacity for global malaria control increases, it is important to examine the allocation of financing in relation to the distribution of populations most at risk of the disease; that is, to measure the equity of disbursements.

A perennial problem facing needs-based allocation of resources for malaria is the quantification of requirements based upon reliable descriptions of national populations at risk of infection and disease burden [12]. We recently published an evidence-based global distribution map of malaria risk that shows the most precise and contemporary description of the spatial limits of stable and unstable P. falciparum risk [13]. In the present study we use descriptions of stable malaria risk to categorize the biological vulnerability of P. falciparum malaria–endemic countries (PMECs) and examine the per capita financial contributions approved by the GFTAM, domestic funding, and support from other donors.

Methods

Defining Populations at Risk of P. falciparum Malaria in 2007

The contemporary spatial distribution of P. falciparum malaria and populations at risk of P. falciparum malaria (PfPAR) are described in detail elsewhere [13]. In brief, data on national case reporting, national and international medical intelligence, climate, and aridity were used to iteratively, and conservatively, define the margins of stable and unstable P. falciparum transmission globally. A definition of stable malaria of a minimum average of one clinical case per 10,000 population per annum (p.a.) in a given administrative unit was used. The historical definitions of stable and unstable malaria are rarely measured, as they are entomologically based metrics. The revised stable-unstable classification of P. falciparum Annual Parasite Incidence was based on a review [14] of the statistical, logistical, programmatic, and pragmatic reasons underpinning the levels used to define action points during the Global Malaria Eradication Programme [14–18]. This definition allows the use of widely available surveillance data that provide a measurable guide to the frequency of malaria exposure at a global level [14]. No transmission was assumed where assembled intelligence stated no malaria risk, because (i) not a single P. falciparum clinical case had been reported to national reporting systems over several years, or (ii) where temperature was too low for sporogony to complete within the average life span of the local dominant vector species, or (iii) conditions were too arid for anopheles mosquito survival. Unstable malaria was used to define areas where transmission was biologically plausible and/or had been documented but where incidence was likely to be less than one case per 10,000 population p.a. [14–18]. We estimated that the global population at any risk of P. falciparum transmission in 2007 was 2.37 billion across 87 countries and included 0.98 billion people living in areas defined as low, unstable transmission risk (see Figure 1).

Country-level extractions of the population densities residing in unstable and stable P. falciparum–endemic areas were undertaken using the Global Rural Urban Mapping Project (GRUMP) alpha version that provides gridded population counts and population density estimates for the years 1990, 1995, and 2000, both adjusted and unadjusted to the United Nations’ national population estimates [19]. We used the adjusted population counts for the year 2000 and projected them to 2007 by applying national, medium variant, intercensal growth rates by country [20] using methods previously described [21]. This resulted in a contemporary global population surface and a 1 × 1 km spatial resolution, describing populations living in unstable and stable P. falciparum–endemic areas in each of the 87 PMECs. The populations at risk were then calculated by overlaying the malaria risk map on the population surface in a geographic information system (ArcView GIS 3.2, ESRI, 1999).

We used populations at any risk of P. falciparum malaria infection and those living in areas of stable transmission as two strata of malaria risk in each country. Stable risk represents a more realistic estimate of populations at risk of significant disease burdens but does not distinguish between those populations exposed to infrequent malaria infection risks and those subject to repeated high infection and thus high disease burden risks [14,22]. In the present analyses, emphasis is given to populations at risk of stable P. falciparum malaria (PFPARStable), as they have the greatest public health needs that can be addressed using combinations of currently proven interventions and are the focus of the Roll Back Malaria (RBM) initiative since 1998 [23,24]. The GFTAM uses eight regional groupings in its presentation of country applications; we have adapted these categories by collapsing the regions into four groupings: Africa, South East Asia/Western Pacific, Middle East/Eastern Europe, and the Americas/Caribbean (the countries in each region are defined in Table S1 and the footnote to Table 1).

We have not developed a similar risk map for the spatial extents of P. vivax. There are important differences in the biology of P. vivax transmission [25,26], the skill with which the parasite can be diagnosed clinically [27], and a less well-defined relationship between transmission intensity and disease outcome. These factors all make an informed cartography and modelling of P. vivax distribution considerably more complex than for P. falciparum. We do not underestimate the likely disease burden of P. vivax malaria [28,29] and recognize that the global extent and public health...
consequences of this parasite remain inadequately defined. It is with this caveat that we have used the risks of the most clinically important and best-mapped human malaria parasite, *P. falciparum*, to articulate biological needs for malaria control investment. In addition, since *P. falciparum* is easier to control [14–18], dealing with this parasite is more often regarded as a national and international priority.

**GFATM-Approved Funding for Malaria Control 2002–2007**

We have focused on approved funding between round one (2002) and round seven (2007), rather than on signed contracts or disbursed funds. Approved funding is the expressed needs of country or region in applications that have been reviewed for technical content and approved by the GFATM. Not all funding has been disbursed and not all contracts would have been signed by the end of 2007; these are difficult to reconcile between rounds of GFATM funding and between countries. Therefore our focus was on the funds approved by the GFATM under the assumption that these approved funds reflect need and do not capture the idiosyncrasies of delayed funding disbursement or cessation of funding due to poor performance or governance [30]. This therefore represents the ability of the GFATM to respond to need, rather than the ability of a government to deliver.

**Table 1. Regional Populations (Millions) at Any and Stable *P. falciparum* Risk in 2007, Annualized GFATM Approved Funding (Millions, US Dollars) and Annualized Non-GFATM Malaria Funding (Millions, US Dollars)**

| Region                  | *PfPAR* Any Risk | *PfPAR* Stable Risk | Annualized GFATM Support | Annualized Non-GFATM Support | Annualized Combined GFATM and Non-GFATM Support |
|-------------------------|------------------|---------------------|--------------------------|-----------------------------|---------------------------------------------|
| Africa                  | 656.3 (27.7%)    | 640.1 (46.1%)       | 312.0 (77.7%)            | 345.8 (58.6%)               | 657.8 (66.3%)                              |
| Americas/Caribbean      | 91.4 (3.9%)      | 41.1 (3.0%)         | 12.8 (3.2%)              | 74.3 (12.6%)                | 87.1 (8.8%)                                |
| South Asia/Western Pacific | 1,479.9 (62.3%) | 655.0 (47.2%)       | 66.5 (16.6%)             | 142.2 (24.1%)               | 208.7 (21.1%)                              |
| Middle East/Europe      | 146.0 (6.2%)     | 52.1 (3.8%)         | 10.5 (2.6%)              | 27.4 (4.6%)                 | 37.9 (3.8%)                                |
| Totals                  | 2,373.6          | 1,388.3             | 401.8                    | 589.7                       | 991.5                                      |

Figures in parentheses are percentages by column totals. Africa: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mayotte, Mozambique, Namibia, Niger, Nigeria, Republic of the Congo, Rwanda, São Tomé and Príncipe, Senegal, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, Togo, Uganda, Zambia, Zimbabwe. Americas/Caribbean: Belize, Bolivia, Brazil, Colombia, Dominican Republic, Ecuador, French Guiana, Guatemala, Guyana, Haiti, Honduras, Nicaragua, Panama, Peru, Suriname, Venezuela. South Asia/Western Pacific: Bangladesh, Bhutan, Cambodia, China, India, Indonesia, Lao People’s Democratic Republic, Malaysia, Myanmar, Nepal, Papua New Guinea, Philippines, Solomon Islands, Sri Lanka, Thailand, Timor-Leste, Vanuatu, Viet Nam. Middle East/East Europe: Afghanistan, Iran, Kyrgyzstan, Pakistan, Saudi Arabia, Tajikistan, Yemen.

doi:10.1371/journal.pmed.0050142.t001
All approved proposals that included a malaria component were assembled from the GFATM Web site [3]. It was difficult to attribute funding to individual countries uniquely where support was awarded for regional initiatives. Such multi-country proposals included those in southern Africa (South Africa, Mozambique, and Swaziland), the Andean region in the Americas (Colombia, Ecuador, Peru, and Venezuela), and the Western Pacific region (Solomon Islands and Vanuatu). In these cases we assumed a proportional allocation by country $P_{PAR}$ relative to the total $P_{PAR}$ for the region (e.g., $P_{PAR}$ estimated for Ecuador is 18.8% of the total $P_{PAR}$ for all four Andean countries combined [5.8 million/30.8 million people]; hence funds assumed for Ecuador were 18.8% of the total funds of the proposal).

Clearly, the approval of awards for malaria by the GFATM has been variable across the 5-y interval. During round one very few malaria awards were approved, representing only 14% of all funds approved in 2002 [31]. In contrast, during round four, a total of US$631 million was awarded to 22 countries. In addition, excluding regional submissions, 21 countries had only a single award approved between rounds one and seven, 35 countries were approved in at least two submissions, and ten countries were approved funding in three or more rounds. Without trying to weigh each timed award per country we have aggregated the combined awards across all approved rounds (one to seven) to represent a single GFATM commitment to each $P_{MEC}$ and taken an annual average of this figure over the 6 y to reflect the averaged approved funding for malaria control per country p.a. This annual estimate has no temporal midpoint, as funds awarded in 2007 have yet to have signed contracts or be disbursed and include the 5 y post-2007, and are simply a p.a. commitment quantified over the number of years of existing funding rounds.

Defining Additional National and External Support for Malaria Control by Country

The GFATM seeks not to displace existing national-level funding for malaria control [1–3], rather to provide additional resources to meet internationally agreed targets. The World Malaria Report (WMR) produced by WHO and UNICEF [32] provides information on the amount of money spent by national governments on malaria control and prevention each year since 1998. These funds are domestic commitments or expenditure on malaria reported by governments to the WHO and converted to US dollars using the contemporary official exchange rate. These data have been used by others to estimate unmet financial needs for malaria control [33], and here we have assumed that the most recent domestic funding figure provided in the WMR is a reflection of (but not the actual) national financial commitment to malaria control. Data for 22 countries were not available in the WMR, and we assumed that these countries were unable or unwilling to provide these data. The wide variation in reported commitments per capita between countries precluded the use of a neighbouring country average. We chose to assume that countries not reporting a domestic funding commitment provided funds equivalent to the lowest rounded figures in their respective regions as follows: Africa US$30,000 p.a.; South East Asia/Western Pacific US$50,000 p.a.; Middle East/Eastern Europe US$100,000 p.a., and the Americas/Caribbean US$100,000 p.a. (Table S1).

Additional malaria-specific support is provided to countries as direct grants or, in the case of the World Bank, as very low interest long-term loans. These additional funding partners include bilateral and multilateral agencies: the UK’s Department for International Development (DFID) supporting Kenya, Nigeria, and Mozambique [34]; the United States Agency for International Development (USAID), which provides recipient country data on its Web site [35]; and the PMI, launched by US President G. W. H. Bush in June 2005 with the aim of spending US$1.2 billion in 15 African countries over 5 y [9]. During the first phase of PMI activities in 2005, three countries were included in the programme (Angola, Tanzania, and Uganda); funding and activities began in an additional four countries in 2007 (Mozambique, Senegal, Malawi, and Rwanda), and although initial consultations have been completed in Benin, Ghana, Mali, Liberia, Ethiopia, Madagascar, Zambia, and Kenya, there are no details of proposed funding allocations for these countries. The World Bank global strategy and booster program has invested US$432 million in 15 countries since 2005, including two new projects approved in Mozambique and Kenya for 2007–2008 [8] and a multi-country, multi-sector programme covering the Senegal River Basin (Senegal, Mali, Mauritania, and Guinea) which was difficult to audit in terms of malaria-specific and country-specific allocations and was therefore excluded from the final analysis (US$42 million for the whole program). Additional World Bank support for periods of between 5 and 7 y from 2002 was assumed as described by Narasimhan and Attaran [36] for ten countries.

Many other important initiatives provide additional support through humanitarian sponsorship or tariffs for commodities [37–39], as part of technical assistance [40], humanitarian assistance [41], broader development assistance from regional banks [42–44], and nongovernment support by varied international and regional NGO partnerships in-country [45–47]. These alternative funding sources were explored through Web searches; however, none of these initiatives provided adequate detail on project-country-specific funding or commodity distribution to enable a comprehensive analysis of committed finances. There were two important exceptions: the Bill & Melinda Gates Foundation US$35 million donation to PATH to support comprehensive malaria control in Zambia between 2005 and 2014 [48] and the Arabian peninsula countries’ 2007 announcement that they would provide US$17 million to Yemen over 5 y to implement its malaria elimination plans [49].

We used information from the World Bank, DFID, USAID, PMI, the domestic funding estimates in the WMR, and the Gates Foundation and Arabian donations to compute a non-GFATM estimate of financial support for malaria control. Data from bilateral, multilateral, or donation support were assembled over multi-year periods between 2004 and 2007 but aggregated to an average in US dollars over the reporting period per donor commitment p.a. per country.

**Results**

Regional *P. falciparum* Risks in Relation to Overall GFATM and Non-GFATM Funding

The vast majority of people living at any risk of *P. falciparum* transmission worldwide are in South East Asia/Western Pacific (62.3%), followed by Africa (27.7%), the Middle East/ East Europe (6.1%), and the Americas/Caribbean (3.8%); Table
1). The numbers, and relative proportion, of the global population at *P. falciparum* risk living in areas of stable endemic malaria are different (Table 1); values are almost equal in Africa (46.1%) and South East Asia/Western Pacific (47.2%). Total estimated *Pf*PAR by country ranged from 58,568 people in Suriname to 950 million in India. *Pf*PAR-stable ranged from approximately 8,000 (Suriname) and 19,000 (Djibouti) to between 130,000 (São Tomé and Príncipe) and 140,000 (French Guiana and Guyana) and to approximately 30–415 million people in eight countries (Pakistan, Tanzania, Myanmar, Ethiopia, the Democratic Republic of Congo, Indonesia, Nigeria, and India). Five countries had no populations living under conditions of stable transmission (Belize, Cape Verde, Mayotte, Tajikistan, and Kyrgyzstan; Table S1).

Seventy-seven countries had been approved for funding for malaria control by the end of 2007, including Georgia, where malaria transmission involves only *P. vivax* and is excluded from the analysis of funding presented here. Table S1 provides country-level estimates of the annual GFATM-approved funding per capita population living in areas of any or stable *P. falciparum* risk from 2002 to 2007. Seventy-six of the 87 *Pf*MECs had been approved funding by round seven, either directly (n = 69) or through regional applications (n = 7), amounting to a total of US$2.41 billion through 133 separate grant applications since round one. Eleven *Pf*MECs have never been awarded GFATM support for malaria (Belize, Botswana, Brazil, Cape Verde, the Democratic Republic of Congo, Dominican Republic, French Guiana, Mayotte, Malaysia, Panama, and Saudi Arabia). Three of these countries have zero *Pf*PAR-stable (Belize, Cape Verde, and Mayotte). Approximately 26.5 million people are at risk of stable transmission in the remaining countries not receiving funding. Total funds approved to countries by the GFATM in a single round ranged between US$1.5 million and US$84.5 million (Table S1). On average, populations living in stable, endemic areas of the world have been approved funding by the GFATM at US$2.9 per capita-at-risk p.a. since 2002. African populations under stable transmission have been awarded US$1.5 annually per capita-at-risk, the Americas/Caribbean US$10.3 per capita-at-risk p.a., Middle East/East Europe US$1.1 per capita-at-risk p.a. and the lowest per capita commitment noted in South East Asia/West Pacific (US$0.7 per capita-at-risk p.a.).

Of the 74 countries with populations exposed to stable endemic transmission that have been allocated malaria funds by the GFATM, the average annual per capita at stable risk awarded amounts ranged from US$0.01 in Myanmar to US$147 in Suriname. Twenty-four countries had an average annual award of more than US$1 per capita at stable risk p.a., 12 were located in Africa and these were predominantly smaller countries (São Tomé and Príncipe, Burundi, Rwanda, Djibouti, The Gambia, Gabon, Equatorial Guinea, and Swaziland [Figure 2; Table S1]). Only seven countries had average annual awarded funding exceeding US$4 per capita at stable risk (São Tomé and Príncipe, Djibouti, Equatorial Guinea, Guyana, Venezuela, Iran, and Suriname [Figure 2; Table S1]).

The enumerated non-GFATM malaria funding to each country amounted to US$589.8 million on an average year between 2002 and 2007, approximately 59% of the estimated combined GFATM and non-GFATM annualized commitments. The non-GFATM funds and their sources are shown by country in Table S1. On an average annual per capita at stable risk basis, the least non-GFATM support per person

---

**Figure 2.** Mean Approved GFATM Funding for 87 PfMECs Expressed as US Dollars (USD) Per Capita at Stable *P. falciparum* Risk Per Annum

Countries indicated by hatching are those with no areas of stable risk.
doi:10.1371/journal.pmed.0050142.g002
was documented in the Philippines (US$0.0023) and the highest amounts in Saudi Arabia (US$19.7), Suriname (US$20.3), and Iran (US$42.4). Twenty-one countries had an average of more than US$1 non-GFATM per capita support for malaria, seven countries had a non-GFATM annual per capita-at-stable risk commitment in excess of US$4; none were located in Africa (Bolivia, Guyana, Iran, Panama, Saudi Arabia, Suriname, and Venezuela; Figure 3; Table S1).

When combined with GFATM per capita support to populations in stable endemic areas, ten countries had an estimated combined per capita annual commitment of more than US$4 per person in an average year (Equatorial Guinea, Panama, São Tomé and Príncipe, Guyana, Bolivia, Venezuela, Saudi Arabia, Djibouti, Iran, and Suriname [Figure 4; Table S1]) compared to 34 countries where the combined annual commitment was less than US$1 per capita at stable risk, including 16 countries where annual malaria support was less than US$0.5 (Figure 4). These 16 countries encompass approximately 710 million people living under conditions of stable transmission, or 50% of the global population exposed to these risks of malaria transmission, and include seven of the poorest countries in Africa (Côte d’Ivoire, Republic of the Congo, Chad, Mali, Democratic Republic of the Congo, Somalia, and Guinea) and two of the most densely populated stable endemic countries in the world (Indonesia and India).

Discussion

Global and Regional Need for Malaria Control Versus Financial Disbursement

*Plasmodium falciparum* malaria continues to cause a huge global disease burden with an estimated 0.5 billion clinical episodes [22] and is the direct cause of over a million deaths in Africa each year [50,51]. The international community has renewed its commitment to its control as a specific component of the MDGs [10,11] and are reconsidering prospects for its elimination in areas where feasible [52,53]. The ten years since the launch of the RBM initiative [24,54] have witnessed a substantial increase in donor assistance to fight malaria.

Between 2002 and 2007 we estimate that a minimum annual average of approximately US$1 billion is committed by the international financing agencies and domestic sources across 87 PfMECs. In these countries 2.37 billion people are at risk of infection, including 1.4 billion people who live in areas where the risks of infection are classified as stable and likely to bear the highest clinical and economic burdens (Table 1). The most important contributor to malaria financing is the GFATM. In the 6 y since the inception of the GFATM, over US$2.4 billion has been approved for funding across 76 PfMECs, 41% of the estimated combined annual support to the *P. falciparum* world. Of the approved funding, most (78%) was targeted at the continent with the highest concentration of people living under conditions of stable transmission and representing the poorest countries globally: Africa (Table 1). Africa also received more than half (59%) of the audited non-GFATM financing, including notable awards made by the bilateral agencies of the US and the UK, the World Bank global strategy and booster program, and PMI.

Given the scarcity of domestic resources and the greatest disease burden across much of the African continent, this allocation of global malaria financing seems appropriate, if taken at face value, but in fact it might not be adequate. Funding commitments by the GFATM and other sources also

---

Figure 3. Mean Approved Non-GFATM Funding for 87 PfMECs Expressed as US Dollars (USD) Per Capita at Stable *P. falciparum* Risk Per Annum

Countries indicated by hatching are those with no areas of stable risk.

doi:10.1371/journal.pmed.0050142.g003
appear to be distributed appropriately among the lowest population at risk areas of the Americas/Caribbean and Mid East/East Europe (Table 1). However, the South East Asia/ Western Pacific region of the world is home to 47% of the global population at risk of stable \( P. falciparum \) transmission, yet these countries were awarded only 17% of the GFATM funding between 2002 and 2007 and 24% of the non-GFATM support, representing a combined annualized per capita at stable risk commitment of approximately US$1 (Table 1). India, Indonesia, and Myanmar combined have approximately 526 million people living under conditions of stable \( P. falciparum \) infection risk, or 38% of the global \( PfPAR \) stable. Yet India has been approved the equivalent of US$0.03 per capita-at-risk of stable malaria p.a. by the GFATM, and its alternative funding sources amount to only US$0.20 per capita-at-risk p.a. (Table S1). GFATM support for Indonesia and Myanmar was equivalent to only US$0.12 and US$0.01 per capita-at-risk p.a., respectively. These are clear examples of the importance of examining financial planning and commitments against objectively mapped criteria of malaria risk. If development goals have a global horizon, reducing the worldwide burden of malaria by 50% by 2015 [10] would fail by a large margin unless international support were directed to those few countries likely to harbour the highest populations at risk.

**Identifying Financial Need for Malaria Control at the National Level**

Country-level examinations of the data revealed that 11 countries have not received any GFATM support but represented extremely low \( n = 7 \) or zero \( n = 3 \) populations exposed to stable \( P. falciparum \) risk and/or had a high domestic support or capacity for malaria control (e.g., Saudi Arabia and Brazil; Table S1). Conversely, the per capita underfunding of India, Indonesia, and Myanmar has been described, but two additional countries should be highlighted for which a low funding commitment is evident when computed as per capita-at-risk. Nigeria, the second-largest \( PfPAR \) stable country in the world with almost 135 million people at risk, was awarded only US$0.12 per capita-at-risk p.a. by the GFATM between 2002 and 2007 (20% of all enumerated per capita investment). Pakistan, with 31 million people at risk, was awarded only US$0.1 per capita p.a. support by the GFATM and has very little domestic or other external support (approximately US$0.016 per capita p.a.).

The example of Suriname shows how much funding can be committed by the GFATM to a comparatively small population at risk and with an existing substantial financial non-GFATM support. Here we found that the GFATM had approved US$147 per capita at stable risk p.a. and the combined commitments to malaria amounted to US$167 per capita p.a. Suriname represents an outlier in the analysis and is expected to achieve rapid scale-up results toward achieving its malaria MDG [55].

We have not analysed the performance consequences of increased international support to malaria since 2002. Analysis of commodity procurements through GFATM has been used to support the successes of the mechanism in reaching international coverage targets rather than actual data on intervention coverage or health impact [4,56]. Claims of performance success by the World Bank [57] have been criticised, as they were not based on validated health impact...
The results published recently by UNICEF and the RBM partnership [59] suggest that progress is being made in some countries, and this progress is assumed to be a direct result of increased availability of funding. There has not been a detailed comparison of performance targets (judged by intervention coverage or health impact) against a per capita financial commitment among populations at risk of \textit{P. falciparum} malaria. Such an analysis will only be possible when a temporally congruent series of country-by-country survey data is assembled. To date only 16 PMECs have national survey data on malaria intervention coverage after 2005 [59].

Auditing international health financing is difficult [36], and our analysis and accompanying data (Table S1) come with additional caveats. The GFATM is transparent in the financial information they provide on funding and is a model for all donors. The precise contribution of funding for malaria control to specific countries by the bilateral donor agencies between 2002 and 2007 is harder to define. First, with the recent exception of USAID and DFID, bilateral agencies make little attempt to provide disease-specific, country-specific accounts. Second, for all development agencies, malaria support is hard to separate from general health sector support or direct-budgetary support that assists human resources, essential drugs, and infrastructure. These contributions are substantial in many resource-poor countries, but there is no obvious method to segregate the malaria-specific component. Estimating domestic expenditure on national malaria control is also difficult to determine. National governments support their health systems to deliver goods and services, and in many African countries the single largest disease burden on the health system is malaria. We have defaulted to using data provided by the WHO on domestic funding for malaria [32] and have assumed that these data include a national government’s audited budgetary allocation under a specified line item labelled “malaria.” Precisely how these figures were presented to WHO remain unclear, for example, whether the reported figures included funds derived from direct budgetary support from bilateral agencies or not. The fidelity of the information is questionable. Malawi was reported to spend US$22.2 million p.a., a country five times smaller than Kenya, which reported only US$0.082 million government commitment, which in turn was half the value supposedly committed by its neighbour, Somalia (US$0.16 million), during a period when the central government in Somalia was not operational.

Defining the financial commitments at country levels, from either provider or recipient sources, limits the overall capacity of financial needs assessments on a country-by-country basis. Increasing pressure on international donors to improve the audited country-by-country transparency in financial commitments will make the sorts of equity analysis presented here possible for all funding partners. National governments, as partners in the RBM partnership, should be encouraged to and assisted in developing better metrics to enumerate annual financial flows to malaria control. RBM is currently undertaking a needs-assessment exercise in 25 African countries, and this should improve the data currently assembled in Table S1.

**The Adequacy of the Global Financial Commitment to Malaria Control**

Most methods of estimating financial need assume a similar costing strategy and package of effective interventions reaching scales of 80% coverage: insecticide-treated nets; indoor-residual house spraying; prevention of malaria in pregnancy; prevention and control of epidemics; effective case management with artemisinin-based combination therapy combined with improved diagnostics; management of severe malaria; and supporting structures such as communication, training, surveillance, and monitoring. The outcomes of these modelled assumptions of need vary considerably globally and regionally, largely as a result of variations in methods used to estimate the denominators of populations at risk.

The earliest attempts by Narasimhan and Attaran [36] estimated that global needs ranged between US$1.5 billion and US$2.5 billion p.a. Recent estimates doubled these figures to between US$3.8 billion and US$4.5 billion p.a. globally with per capita needs for Africa of US$2.43, for Asia and Oceania of US$1.16, and for the Americas of US$0.86 in 2006 [33]. Using a different denominator, Teklehaimanot et al. [60] estimated that the per capita needs for effective scaling up of malaria control was US$4.46 in Africa in 2007, or a combined commitment from all sources of approximately US$3 billion.

Using the range of predicted annual needs we estimate that there remains a 50%–450% shortfall of funding to achieve the scaling up of malaria control required worldwide. It should be noted that these estimates are only for the scaling up of control and do not even consider the additional financing that might be required for malaria elimination, where feasible. This shortfall is particularly acute in several high population density countries with stable \textit{P. falciparum} malaria risk. In Africa, where it will be difficult to increase domestic financing appreciably before 2015, there is still a possible 80%–90% deficit in per capita funding for effective malaria control.

**Analyses, Caveats, and Future Perspectives**

There are important epidemiological heterogeneities within our definition of stable malaria, ranging from less than one infectious bite from local dominant vectors per person per year to over ten new infections per person per night. The prevalence of infection in a community is a useful guide to the variation in intensity of transmission within areas of stable endemicity [14,61,62]. In addition, it was recently demonstrated that the prevalence of infection is lower across the stable endemic areas of the Americas, much of Asia, and a larger part of Africa than was previously assumed [13]. The public health consequences of \textit{P. falciparum} in areas of low transmission intensity will be considerably less than those in areas of more intense transmission [22,64]. However, even in areas of high transmission the relationship between disease and its outcome is nonlinear and complex [22,63,64]. We have not adjusted our analysis of funding allocation according to the intensity of transmission within and between the stable \textit{P. falciparum}-endemic countries for three reasons. First, there is no adequate description of transmission intensity across the World that is related to parameters that can be used to define the public health burdens at country levels. Second, the GFATM and RBM do not currently have a working model or definition of the projected public health benefits resulting from financing different intervention mixes of known efficacy under different starting transmission conditions. Hence, the GFATM uses overall populations at risk rather than transmission intensity, vector species, or other proximate determinants of infection risk as its guiding mantra for
resource allocation [1,6]. Third, we have assumed that a standard mix of interventions would be required to meet the objectives of RBM that were laid out in the late 1990s. As the malaria control community and many individual countries reconsiders prospects for the elimination of malaria where feasible, resource needs and matched financial expectations may change. It is not clear whether the financial needs of a country predominantly exposed to intense, stable *P. falciparum* malaria transmission are greater than those of a country whose dominant transmission characteristics are of low intensity. The interventions and their delivery mechanisms may become more expensive as countries prepare to target focal pockets of infection risk and prevent the re-entry of transmission into malaria-free areas. The use of stable, endemic, high disease–burden definitions of populations at risk may change, and it may become more “acceptable” to consider unstable transmission–risk populations as a target for funding. We believe that the uncertainty around priority setting based on risk, intervention selection, and the consequent planning of financial needs requires a clear approach by the GFATM, RBM, and their partners, informed by the baseline endemicity of malaria within the stable limits of *P. falciparum* malaria transmission.

With these caveats our analysis has focussed on appropriate allocations based on overall *PPar*, but it has not examined the adequacy of funding. Nor have we considered the political dimensions of international health financing, for example, whether donor agencies should provide external support to countries with corrupt administrations or to those whose general governments spend much less on public health than on military expansion. These questions are beyond the scope of the present analysis, but we hope that the biological risk and country-level funding data in Table S1 offer a combined basis for examining other dimensions and nuances of malaria financing.

Conclusion

That more funding is needed to control *P. falciparum* malaria is not a new concept, but our analysis highlights the reality that more is needed in specific countries and regions to ensure that the highest concentrations of people at risk benefit from international support. Without a selective epidemiological–economic targeting of global malaria control investment it seems unlikely that international goals to halve disease burdens by 2015 will be achieved.

Supporting Information

Table S1. *PPar* in 2007 and Malaria Funding Per Annum by Country Found at doi:10.1371/journal.pmed.0050142.s001 (52 KB XLS).

Acknowledgments

We thank Abdilsalan Mohamed Noor and Dave Smith for their comments on earlier drafts of the manuscript. The authors acknowledge the support of the Kenyan Medical Research Institute (KEMRI). This paper is published with the permission of the director of KEMRI.

Author contributions. RWS wrote the manuscript. RWS, CAG, and JJM assembled the financial information. RWS, CAG, and SIH developed and implemented the methods to define the *P. falciparum* populations at risk data. All authors contributed to the final editing of the manuscript.

References

1. GFATM (2007) The framework document of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Title, purpose, principles and scope of the fund. Geneva: GFATM. Available: http://www.theglobalfund.org/en/files/publicloc/Framework_.uk.pdf. Accessed 28 January 2008.
2. GFATM (2007) The Global Fund. Who we are what we do. Geneva: GFATM. Available: http://www.theglobalfund.org/en/media_center/publications/ brochure/. Accessed 28 January 2008.
3. GFATM (2008) Investing in our future. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Geneva: GFATM. Available: http://www. theglobalfund.org/. Accessed 28 January 2008.
4. Feachem RGA, Sabot OJ (2006) An examination of the Global Fund at 5 years. Lancet 368: 537–540.
5. Nahlen BL, Low-Beer D (2007) Building to collective impact: the global fund support for measuring reduction in the burden of malaria. Am J Trop Med Hyg 77: 321–327.
6. GFATM (2007) Resource needs: funding the global fight against HIV/AIDS, tuberculosis and malaria. Geneva: GFATM. Available: http://www. theglobalfund.org/en/files/about/fulfillment/replenishment/assessment_report_.en.pdf. Accessed 28 January 2008.
7. GFATM (2006) Report of the Policy and Strategy Committee. Thirteenth board meeting, 26–27 April 2006. Geneva: GFATM. Available: http://www. theglobalfund.org/en/files/board/meeting13/GF-B13-7_Report_of_the___Policy_and_ Strategy_Committee.pdf. Accessed 28 January 2008.
8. World Bank (2007) The World Bank global strategy and booster program. Washington (D.C.): World Bank. Available: http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/EXTHEALTHNUTRITIONANDPOULATION/EXTMALARIA00_contentMDK:20461038-pagePK:210058-piPK:210062-theSitePK:375598.00.html. Accessed 28 January 2008.
9. PMI (2007) President’s Malaria Initiative. Saving the lives of mothers and children in Africa. First annual report, March 2007. Washington (D.C.): President’s Malaria Initiative (PMI). Available: http://www.fightingmalaria.govresources/psm_annual_report.pdf. Accessed 28 January 2008.
10. MDG (2008) UN Millennium Development Goals. New York: United Nations. Available: http://www.un.org/millenniumgoals/. Accessed: 28 January 2008.
11. Sachs JD (2004) Health in the developing world: achieving the Millennium Development Goals. Bull World Health Organ 82: 847–849.
12. Hay SI, Snow RW (2006) The Malaria Atlas Project: developing global maps of malaria risk. PLoS Med 3: e475. doi:10.1371/journal.pmed.0030473.
13. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, et al. (2006) The limits and intensity of *Plasmodium falciparum* transmission: implications for malaria control and elimination worldwide. PLoS Med 5: e58. doi:10.1371/journal. pmed.0050038.
14. Hay SI, Smith DL, Snow RW (2008) Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect Dis 8: 569–578.
15. Pampena E (1969) A textbook of malaria eradication. 2nd edition. London: Oxford University Press. 593 p.
16. Swaaroop S, Gilroy AB, Uemura K (1960) Problems of epidemiology in malaria eradication. WHO/CDS/RBM/2000.17. Geneva: RBM. Available: http://www.rollbackmalaria.org/docs/ theAfricanSummitOnRollBackMalaria,Abuja,25April2000.WHO/CHDS/ RBM/2000.17. Geneva: RBM. Available: http://www.rollbackmalaria.org/docs/ abuja_declarations.pdf. Accessed 28 January 2008.
17. Swaaroop S, Gilroy AB, Uemura K (1960) Problems of epidemiology in malaria eradication. WHO/CDS/RBM/2000.17. Geneva: RBM. Available: http://www.rollbackmalaria.org/docs/ theAfricanSummitOnRollBackMalaria,Abuja,25April2000.WHO/CHDS/ RBM/2000.17. Geneva: RBM. Available: http://www.rollbackmalaria.org/docs/ abuja_declarations.pdf. Accessed 28 January 2008.
18. Balk DL, Deichmann U, Yetman G, Pozzi F, Hay SI, et al. (2006) Determining global population distribution: methods, applications and data. Adv Parasitol 62: 119–156.
19. UNPOP (2006) World population prospects: the 2006 revision population database. New York: United Nations Population Division (UNPOP). Available: http://esa.un.org/unpp/. Accessed: 28 January 2008.
20. Hay SI, Noor AM, Nelson A, Tatem AJ (2005) The accuracy of human population maps for public health application. Trop Med Int Health 10: 1073–1086.
21. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of *Plasmodium falciparum* malaria. Nature 434: 214–217.
22. RBM (2002) The Abuja declaration and the plan of action. An extract from the African Summit on Roll Back Malaria, Abuja, 25 April 2000. WHO/CHDS/ RBM/2000.17. Geneva: RBM. Available: http://www.rollbackmalaria.org/docs/ abuja_declaration.pdf. Accessed 28 January 2008.
23. RBM (2008) The Roll Back Malaria partnership. Geneva: Roll Back Malaria. Available: http://www.rbm.who.int/. Accessed: 28 January 2008.
24. Rosenberg R (2007) *Plasmodium vivax* in Africa: hidden in plain sight? Trends Parasitol 23: 193–196.
25. Sattabongkot J, Tsuboi T, Zoller GE, Sirirachaxinthorn J, Cui LW (2004) *Plasmodium vivax* transmission: chances for control? Trends Parasitol 20: 192–198.
26. Maxcy M, Pukrittayakamee S, Newton PN, White NJ (2004) Mixed-species malaria infections in humans. Trends Parasitol 20: 233–240.
27. Baird JK (2007) Neglect of *Plasmodium vivax* malaria. Trends Parasitol 23: 533–539.
28. Price RN, Tjitra E, Guerra CA, White NJ, Anstey NM (2007) *Vivax* malaria: neglected and not benign. Am J Trop Med Hyg 77: 79–87.
29. Lu C, Michael C, Khan K, Murray CJL (2006) Absorptive capacity and
Financing Global Malaria Control

disbursements by the Global Fund to Fight AIDS, Tuberculosis and Malaria: analysis of grant implementation. Lancet 368: 483–488.
31. Teklehaymanot A, Snow RW (2002) Will the Global Fund help roll back malaria in Africa? Lancet 360: 885–889.
32. WHO (2005) World Malaria Report 2005. Geneva: World Health Organization (WHO). Available: http://www.rbm.who.int/wmr2005/. Accessed: 28 January 2008.
33. Kiszewski A, Johns B, Schapira A, Delacollette C, Crowell V, et al. (2007) Estimated global resources needed to attain international malaria control goals. Bull World Health Organ 85: 625–630.
34. Department for International Development (2007) Malaria fact sheet. London: DFID. Available: http://www.dfid.gov.uk/pubs/files/mdg-factsheets/ malariafactsheet.pdf. Accessed: 28 January 2008.
35. USAID (2008) USAID from the American people. Washington (D. C.): United States Agency for International Development (USAID). Available: http://www.usaid.gov/. Accessed: 28 February 2008.
36. Narasimhan V, Attaran A (2003) Roll back malaria? The scarcity of international aid for malaria control. Malar J 2: 8.
37. Malaria No More (2008) Malaria No More. Take the giving challenge. New York: Malaria No More. Available: http://www.malarianomore.org. Accessed: 28 January 2008.
38. UNITAID (2008) UNITAID. Making globalization equitable. Geneva: UNITAID. Available: http://www.unaid.org/how-it-is-financed.html. Accessed: 28 January 2008.
39. World Swim against Malaria (2008) Welcome to World Swim against Malaria. London: World Swim against Malaria. Available: http://www.worldswimagainstmalaria.com. Accessed: 28 January 2008.
40. Clinton Foundation (2008) William J. Clinton Foundation. New York: Clinton Foundation. Available: http://www.clintonfoundation.org. Accessed: 28 January 2008.
41. Médecins sans Frontières (MSF) (2008) Médecins sans Frontières (MSF). Available: http://www.msf.org. Accessed: 28 January 2008.
42. African Development Bank Group (2008) African Development Bank Group. Building today, a better Africa tomorrow. Abidjan: African Development Bank Group. Available: http://www.afdb.org. Accessed: 28 January 2008.
43. Asian Development Bank (2008) Asian Development Bank. Fighting povert in Asia and the Pacific. Metro Manila: Asian Development Bank. Available: http://www.adb.org. Accessed: 28 January 2008.
44. Islamic Development Bank (2008) Islamic Development Bank. Together we build a better future. Jeddah: Islamic Development Bank. Available: http://www.isdb.org. Accessed: 28 January 2008.
45. African Medical Research Foundation (2008) African Medical Research Foundation. Nairobi: African Medical Research Foundation. Available: http://www.amref.org. Accessed: 28 January 2008.
46. Merlin (2008) Merlin. Medical relief, lasting care. London: Merlin. Available: http://www.merlin.org.uk. Accessed: 28 January 2008.
47. World Vision International (2008) World Vision International: World Vision International. Available: http://www.wvi.org. Accessed: 28 January 2008.
48. PATH (2008) New partnership launched to accelerate and evaluate national malaria control program in Africa. Seattle: PATH. Available: http://www.path.org/news/pr-030519-macepa.php. Accessed: 28 January 2008.
49. WHO (2006) Malaria and Children. Progress in Intervention Coverage. New York: The United Nations Children’s Fund (UNICEF). Available: http://www.unicef.org/health/files/MalariaOct6forweb_final.pdf. Accessed: 28 January 2008.
50. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JRA, et al. (2006) The burden of malaria mortality among African children in the year 2000. Int J Epidemiol 35: 691–704.
51. Snow RW, Craig M, Deschmann U, Marsh K (1999) Estimating mortality, morbidity and disability due to malaria among Africa’s non-pregnant population. Bull World Health Organ 77: 624–640.
52. Roberts L, Enserink M (2007) Did they really say . . . eradication? Science 318: 1544–1545.
53. Feachem R, Sabot O (2008) A new global malaria eradication strategy. Lancet 10: 1653–1655.
54. Nabarro DN, Taylor EM (1998) The “Roll Back Malaria” campaign. Science 280: 2067–2068.
55. Smith C (2007) Suriname has ‘already hit’ malaria MDG. London: Science and Development Network. Available: http://www.scidev.net/content/news/ eng/suriname-has-already-hit-malaria-mdg.cfm. Accessed: 28 January 2008.
56. Komatsu R, Low-Beer D, Schwartlander B (2007) Global Fund-supported programmes contribution to international targets and the Millennium Development Goals: an initial analysis. Bull World Health Organ 85: 805–811.
57. Barat LM (2006) Four malaria success stories: how malaria burden was successfully reduced in Brazil, Eritrea, India, and Vietnam. Am J Trop Med Hyg 74: 12–16.
58. Bate R (2008) World Bank matrix malaria booster program an analysis. Washington (D. C.): Africa Fighting Malaria. Available: http://www.fightingmalaria.org/pdfs/WB_matrixcomment.pdf. Accessed: 28 January 2008.
59. UNICEF (2007) Malaria and Children. Progress in Intervention Coverage. New York: The United Nations Children’s Fund (UNICEF). Available: http://www.unicef.org/health/files/MalariaOct6forweb_final.pdf. Accessed: 28 January 2008.
60. Nabarro DN, Maller JD (2007) Scaling up malaria control in Africa: an economic and epidemiological assessment. Am J Trop Med Hyg 77: 138–144.
61. Smith DL, McKenzie FE (2004) Statics and dynamics of malaria infection in African children. Adv Parasitol 52: 235–264.
62. Smith DL, Dushoff J, Snow RW, Hay SI (2005) The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature 438: 492–495.
63. Snow RW, Marsh K (2002) The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 52: 235–264.
64. Trape JF, Rogier C (1996) Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12: 236–240.
Editors’ Summary

Background. Malaria is one of the most common infectious diseases in the world and one of the greatest global public health problems. The Plasmodium falciparum parasite causes approximately 500 million cases each year and over one million deaths. More than 40% of the world’s population is at risk of malaria.

The Millennium Development Goals (MDGs), established by the United Nations in 2000, include a target in Goal 6: “to have halted by 2015 and begun to reverse the incidence of malaria and other major diseases.” Following the launch of the MDG and international initiatives like Roll Back Malaria, there has been an upsurge in support for malaria control. This effort has included the formation of the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and considerable funding from the US President’s Malaria Initiative, the World Bank, the UK Department for International Development, USAID, and nongovernmental agencies and foundations like the Bill & Melinda Gates Foundation. But it is not yet clear how equitable or effective the financial commitments to malaria control have been.

Why Was This Study Done? As part of the activities of the Malaria Atlas Project, the researchers had previously generated a global map of the limits of P. falciparum transmission. This map detailed areas where risk is moderate or high (stable transmission areas where malaria is endemic) and areas where the risk of transmission is low (unstable transmission areas where sporadic outbreaks of malaria may occur). Because the level of funding to control malaria should be proportionate to the size of the populations at risk, the researchers in this study appraised whether the areas of greatest need were receiving financial resources in proportion to this risk. That is, whether there is equity in how malaria funding is allocated.

What Did the Researchers Do and Find? To assess the international financing of malaria control, the researchers conducted a audit of financial commitments to malaria control of the GFATM, national governments, and other donors for the period 2002 to 2007. To assess need, they estimated the population at risk of stable P. falciparum malaria transmission in 2007, building on their previous malaria map. Financial commitments were identified via online and literature searches, including the GFATM Web site, the World Malaria Report produced by WHO and UNICEF, and various other sources of financial information. Together these data allowed the authors to generate an estimate of the annual malaria funding allocation per capita population at risk of P. falciparum.

Of the 87 malaria-endemic countries, 76 received malaria funding commitments by the end of 2007. Overall, annual funding amounted to US$1 billion dollars, or less than US$1 per person at risk. Forty percent came from the GFATM, and the remaining from a mix of national government and external donors. The authors found great regional variation in the levels of funding. For example, looking at just the countries approved for GFATM funding, Myanmar was awarded an average annual per capita-at-risk amount of US$0.01 while Suriname was awarded US$147. With all financial commitments combined, ten countries had per capita annual support of more than US$4 per person, but 34 countries had less than US$1, including 16 where annual malaria support was less than US$0.5 per capita. These 16 countries represent 50% of the global population at risk and include seven of the poorest countries in Africa and two of the most densely populated stable endemic countries in the world (India and Indonesia).

What Do These Findings Mean? The researchers find that the distribution of funds across the regions affected by malaria to be generally appropriate, with the Africa region and low-population-at-risk areas such as the Americas, the Caribbean, the Middle East, and Eastern Europe receiving proportionate annual malaria support. But they also identify large shortfalls, such as in the South East Asia and Western Pacific regions, which represents 47% of the global population at risk but received only 17% of GFATM and 24% of non-GFATM support. National government spending also falls short: for example, in Nigeria, where more than 100 million people are at risk of stable P. falciparum transmission, less than US$1 is invested per person per year. These findings illustrate how important it is to examine financial commitments against actual needs. Given the gaps between funding support and level of stable P. falciparum risk, the authors conclude that the goal to reduce the global burden of malaria by 2015 very likely will not be met with current commitments. They estimate that there remains a 50%–450% shortfall in funding needed to scale up malaria control worldwide.

Future research should assess the impact of these funding commitments and what additional resources will be needed if goals of malaria elimination are added to malaria control targets.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0050142.

- This study is discussed further in a *PLoS Medicine* Perspective by Anthony Kiszewski
- The authors of this article have also published a global map of malaria risk; see Guerra, et al. (2008) *PLoS Med* 5(2) e38
- Information is available from the Global Fund to Fight AIDS, Tuberculosis and Malaria
- More information is available on global mapping of malaria risk from the Malaria Atlas Project